Arcutis Biotherapeutics, Inc. (ARQT) Reports Improved Caregiver Outcomes in Infant Trial
Arcutis Biotherapeutics reported improved caregiver outcomes in a trial of 101 infants using ZORYVE for atopic dermatitis. The sNDA is under FDA review with a target action date of February 23, 2027. This is part of an ongoing effort to expand the drug's pediatric use.
